Turn this list into pipeline.
Biotech Companies in Newcastle upon Tyne: 25 Active Firms (2026)
Biotech companies in Newcastle upon Tyne develop life-sciences technologies, therapeutics and research tools across the city’s wider metropolitan area.
Commercial demand tends to sit in specialist buying centres rather than general software-style budgets: drug discovery teams, translational research groups, laboratory operations, diagnostics functions and life-sciences commercialisation teams. Buyers are usually other businesses, research organisations or regulated healthcare-adjacent operators, with procurement shaped by evidence quality, scientific credibility and regulatory readiness. Engagements are more often paid pilots, contracted research support, platform access, assay or tool supply, and clinical-development services than high-volume product sales. The typical local target appears to be the revenue-generating small or lower-mid-market customer, where a compact technical workforce can still support regulated delivery.
Read more
Newcastle upon Tyne has 25 actively trading biotech companies, making the local base a compact specialist cluster rather than a broad national-scale market. Reported employment across the cohort totals 128 people, which points to a workforce concentrated in small scientific, technical and commercial teams. The profile fits revenue-generating businesses working around therapeutics, platform biology, diagnostics, research tools and enabling technology, with commercial traction likely to be measured through contracted research, lab adoption, licensing discussions and clinical-development relationships rather than consumer distribution.
Medicines development and clinical-support activity sits inside the UK life-sciences framework overseen by the MHRA. Its remit includes clinical trial applications, marketing authorisations, drug licences and post-authorisation pharmacovigilance, while clinical trials also have to satisfy Good Clinical Practice, ethics review and informed-consent requirements. Market access can add another layer when approved medicines face assessment by health technology bodies before routine use in publicly funded healthcare. Trade-body coverage is split by emphasis: the BioIndustry Association represents biotech and life-sciences businesses, while the ABPI focuses on research-based pharmaceutical companies.
The local cohort appears weighted towards early-commercial specialists rather than scale-up drug developers. Progress tends to depend on repeatable evidence packages, access to clinical or laboratory partners, and the ability to carry regulated work without stretching compact teams. Scarcity of larger revenue-stage businesses may keep acquisition and partnership routes more visible than standalone expansion for many firms. The more durable operators are likely to be those that can turn scientific capability into regulated services, licensing options or research-tool adoption, while avoiding long unfunded development cycles.
25
Active firms
2026
3
Above £5M
Companies over the revenue threshold
5
New incorporations
Incorporated since 2022
Key facts
About 12% of the trading cohort reports turnover above £5M (3 of 25 firms) — the rest sits below that revenue band.
20% of the cohort was incorporated since 2022 (5 firms), so a sizeable share is in its first few filing cycles.
The MHRA sets UK standards for medicines and evaluates new treatments, including clinical trial applications, marketing authorisations, drug licences and pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements, with NICE review relevant for routine NHS use after approval.
The Office for Life Sciences estimated that the UK life-sciences industry comprised 6,170 businesses across 7,320 companies in 2023/2024, generating £146.9 billion in turnover.
The biopharmaceutical subsector generated £98.9 billion in turnover in 2023/2024, accounting for 67% of total UK life-sciences turnover.
UK biotech raised £3.5 billion in equity investment in 2024, a 94% increase on 2023, with the BIA noting concentration in a small number of large rounds mainly from US investors.
Top Newcastle upon Tyne Biotech companies
FIBROFIND LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides preclinical drug development services using human tissue precision‑cut slice models to study fibrotic diseases. Conducts research and testing for pharmaceutical development focused on liver,…
Serves pharmaceutical and biotech drug development teams and researchers working on preclinical therapies for fibrotic liver, kidney and lung diseases.
Financial Health
StrongStrong · Growing, Hiring · 10% CAGR over 4y
Location
PXD Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops orthopaedic diagnostics, including a genetic test (Orthotype) that assesses patient risk of implant failure. Performs laboratory analysis of retrieved orthopaedic implants to evaluate wear…
Serves orthopaedic healthcare professionals, clinics and hospitals managing joint implant patients, with a patient-facing route for individuals concerned about orthopaedic implant failure.
Financial Health
StableStable · Hiring · 11% CAGR over 4y
Location
3D BIO-TISSUES LIMITED
Trajectory
5y · 2019–NowFinancial sub-scores
Computed from 5 filingsDevelops tissue engineering technologies to produce bio‑equivalent tissues using cell‑based manufacturing and a tissue‑templating process. Conducts biotechnology research and develops products for…
Sells to biotech, life-science and cellular agriculture organisations, including teams working on tissue engineering, corneal/skin models, cultivated meat and lab-grown leather.
Financial Health
StableStable · Hiring · 67% CAGR over 5y
Location
Marrabio Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and supplies engineered Cytocaf proteins used as defined, xeno-free materials for mammalian cell culture, including fibronectin and vitronectin-based coatings that replace extracellular…
Serves biotechnology and life science researchers, academic labs, and companies working with mammalian cell culture, stem cells/iPSCs, and cell-based R&D.
Financial Health
StrongStrong · Growing, Hiring · 200% CAGR over 2y
Location
Nanovery Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops DNA nanotechnology-based bioanalysis tools for detecting and quantifying nucleic acids. Provides nanorobotic sensor assays for RNA therapeutics, siRNA and antisense oligonucleotide analysis,…
Serves biotechnology and pharmaceutical R&D teams, bioanalysis laboratories and researchers working on RNA therapeutics, ASO/siRNA programmes and microRNA biomarkers.
Financial Health
WeakWeak · Hiring · 93% CAGR over 4y
Location
Hexislab Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops AI‑driven platforms for discovery and testing of bioactive ingredients and product formulations. Provides in‑silico analysis, assay testing and scientific validation to support cosmetics,…
Serves beauty, skincare, personal care and wellness brands, including large consumer goods companies and product developers, plus pharmaceutical clients seeking new ingredients, formulations and…
Financial Health
DistressedDistressed · Hiring · 4% CAGR over 4y
Location
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
ESP Diagnostics Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong
Location
AtlasBiomics Ltd
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
Alcyomics Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services using human in vitro assays and 3D tissue models to test safety and efficacy of drugs, biologics, medical devices and chemicals, including immunotoxicity testing,…
Sells to businesses in life sciences and regulated product development, including pharma, biotech, medical device and cosmetics companies developing cellular therapies, biologics, small molecules,…
Financial Health
StableStable · Hiring · 7% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong
Location
MediBiotix Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
PharmaBiotix Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
CleanBiotix Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
CELLFLUIDX LTD
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
HealthyHealthy · 0% CAGR over 4y
Location
NUNABIO LIMITED
Trajectory
5y · 2023–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies synthetic DNA using cell‑free production technology. Provides contract development and manufacturing services and distributed micro‑foundry systems for producing DNA constructs…
Serves biotech and pharmaceutical researchers, therapy and vaccine developers, advanced materials manufacturers, and government partners from discovery through clinical and commercial development.
Financial Health
StrongStrong · Growing, Hiring · 22% CAGR over 3y
Location
BIOTECH IMPROVEMENTS GROUP LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy
Location
IMMUNODIAGNOSTIC SYSTEMS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops, manufactures and distributes in‑vitro diagnostic products for clinical and research laboratories, including automated immunoassay systems, ELISA and chemiluminescence assays, instruments…
Serves B2B clinical and research laboratories, diagnostic testing providers, and life science researchers working in endocrinology, autoimmunity, infectious disease, allergy, animal research, and…
Financial Health
HealthyHealthy · -90% CAGR over 2y
Location
HISTOCYTE LABORATORIES LTD
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies cell‑based quality control materials for immunohistochemistry and in situ hybridization, including formalin‑fixed paraffin‑embedded cell line controls provided as slides or…
Serves B2B pathology and diagnostic laboratory customers, especially immunohistochemistry and in-situ hybridization teams in hospitals, research organisations and clinical trials, plus international…
Financial Health
HealthyHealthy · -62% CAGR over 4y
Location
MDNA LIFE SCIENCES (UK) LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops molecular diagnostic tests that analyse mitochondrial DNA biomarkers in blood samples to detect diseases such as cancer. Uses proprietary Mitomic technology to support early, non‑invasive…
Serves a mix of healthcare organisations, clinicians and patients, particularly those involved in assessing difficult-to-diagnose diseases such as cancer; also targets medical partners in diagnostics…
Financial Health
WeakWeak · -75% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides laboratory research services for clinical studies, including ultrasensitive multiplex immunoassays for protein biomarker measurement, immune therapy monitoring, gene expression RNA‑seq and…
Serves biopharma companies, clinical research teams and translational medicine groups running immunotherapy studies, particularly those working with clinical samples, biomarkers, gene expression and…
Financial Health
StableStable · -71% CAGR over 4y
Location
Supplies clinical laboratory diagnostic instruments and testing systems, including electrophoresis analyzers, coagulation and platelet function testing devices, ELISA assays, and colorectal screening…
Serves B2B healthcare laboratories, including hospital, reference and clinical diagnostic labs, with buyers such as lab directors, biomedical scientists and procurement teams managing high-throughput…
Location
Haimachek UK Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops minimally invasive in vivo biomarker technology and medical devices that capture and isolate rare cells from the bloodstream to support earlier disease detection and personalised treatment…
Serves hospitals, clinicians and clinical research partners in cardiology and oncology, particularly those working with heart disease, cancer, diabetes and related patient populations.
Financial Health
WeakWeak · Hiring · 6% CAGR over 4y
Location
V.H. Bio Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsSupplies and distributes life science research and diagnostic products, including reagents, antibodies, PCR and sequencing tools, and transplant diagnostics. Also provides laboratory services such as…
Serves clinical, diagnostic, research and teaching laboratories in the UK and Republic of Ireland, particularly transplant, molecular biology, immunology and cell biology teams in hospitals,…
Financial Health
StrongStrong · Profitable, Growing · 4% CAGR over 2y
Location
Jetbio Ltd
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · Hiring · 5% CAGR over 5y
Location
Unlock all 25 leads
Showing 26 of 25 — +0 more with verified decision-maker contacts, live data, and CRM sync.
How Newcastle upon Tyne Biotech companies work and how to sell to them
What they do
Newcastle upon Tyne biotech firms usually make money before any consumer-facing scale arrives, through contracted research, laboratory services, assay development, tool supply, platform access and licensing options. Therapeutics companies may run on collaboration income, milestone payments and option-to-license structures while product evidence is built; diagnostics and research-tool companies more often charge per study, per sample, per instrument workflow or through annual access and support fees. Services-led work can look like project pricing or retained scientific capacity. A smaller cohort has passed £5M revenue, so many commercial discussions still centre on repeatable pilots, referenceable lab use and evidence that a buyer can defend internally.
Who they sell to
Customers are typically scientific and regulated buyers: biopharma R&D groups, clinical-development teams, diagnostics operators, research organisations, university-linked commercial teams and healthcare-adjacent providers. The economic buyer is often a chief scientific officer, head of translational research, lab director, head of quality, procurement lead or finance director, depending on whether the purchase concerns evidence generation, workflow capacity or regulated delivery. Self-serve buying is uncommon beyond low-value tools. Most larger engagements move through direct sales, technical validation, legal review and quality checks; partner-led routes matter where academic, clinical or contract-research relationships create credibility before procurement becomes formal.
What they buy
Most biotech firms tend to spend on tools that protect scarce scientific time and make evidence easier to reproduce. Common categories include laboratory information management, electronic lab notebooks, sample tracking, bioinformatics pipelines, cloud compute, clinical-data capture, quality management, document control, information security and finance systems. Smaller teams also buy outsourced regulatory writing, intellectual-property support, accounting, grant administration, recruitment, specialist insurance, lab equipment maintenance, facilities services and cold-chain logistics. Sellers should expect buying committees to ask for validation, audit trails, permission controls, implementation effort and references from comparable regulated life-sciences users, rather than generic productivity claims.
Why and how to sell to them
Buying intent often appears when a biotech firm moves from grant-backed research into repeatable commercial delivery, signs a new research collaboration, prepares an MHRA-facing submission, hires senior scientific or quality leadership, opens or extends lab capacity, or starts selling beyond founder-led relationships. The pain is usually not lack of ideas; it is converting scarce specialist capacity into auditable work, credible evidence and revenue without adding administrative load. Outbound messages tend to land better when they reference the buyer’s development stage and regulated workflow, then offer a narrow reduction in risk, cycle time, compliance burden or manual handover.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Newcastle upon Tyne
Related directories
Frequently asked questions
How many biotech companies are there in Newcastle upon Tyne?
What counts as a biotech company in this list?
Which are the largest biotech companies in Newcastle upon Tyne?
What do biotech companies in Newcastle upon Tyne actually do?
How does Newcastle upon Tyne biotech compare internationally?
How is this list built and how fresh is the data?
How big are the typical biotech companies in Newcastle upon Tyne?
Are these mostly new or established biotech companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 25 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.